· Published by Health Canada · Official notice
| Lot | Brand | Product Name | Market Authorization | Dosage Form | Strength |
|---|---|---|---|---|---|
| D10776B | JAMP ATORVASTATIN CALCIUM | JAMP ATORVASTATIN CALCIUM 10 mg | DIN 02504197 | Tablet | ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG |
| D10776B | JAMP ATORVASTATIN CALCIUM | JAMP ATORVASTATIN CALCIUM 40 mg | DIN 02504219 | Tablet | ATORVASTATIN (ATORVASTATIN CALCIUM) 40 MG |
Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.
Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.
Product from the affected lot was sold to pharmacies between May 2022 and August 2022.
Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side.
Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.
Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.